Wells Fargo Maintains Overweight on Rapport Therapeutics, Raises Price Target to $46
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and raises the price target from $43 to $46.
Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and raises the price target from $43 to $46.